Previous studies have shown this therapy upregulates neurotrophins, including VEGF and endothelial nitric oxide synthase (eNOS), in animal models of heart disease, vascular dementia, and Alzheimer’s disease ([8, 9]; S. H. [10]). This evidence concerns the gene NOS3 and vascular dementia.